nadja salomon - Nanotechnology

Author Information

Nadja Salomon is affiliated with TRON, Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH, located in Mainz, Germany. She has made significant contributions to the field of cancer immunotherapy and nanotechnology, focusing on innovative treatments for various types of cancer.

Research Contributions

Nadja Salomon has made substantial contributions to the field of cancer immunotherapy. Her research primarily focuses on the development and therapeutic efficacy of RNA vaccines, targeting tumor vasculature, and enhancing the antitumor activity of local radiotherapy. She has been involved in preclinical studies and has reported on significant findings in the application of mRNA therapeutics. Her work has implications for improving cancer treatment outcomes and advancing the understanding of immune responses to cancer.

Aliases

No aliases were provided for Nadja Salomon.

Publication and Citation Metrics

Metric	Value
Citation Count	237
h-index	6
Paper Count	10

Publications:

Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer

DOI: 10.1007/s00262-021-03134-9

Year: 2021

mRNA therapeutics in cancer immunotherapy

DOI: 10.1186/s12943-021-01348-0

Year: 2021

Targeting the tumor vasculature with engineered cystine-knot miniproteins

DOI: 10.1038/s41467-019-13948-y

Year: 2020

A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice

DOI: 10.1080/2162402X.2020.1771925

Year: 2020

A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo

DOI: 10.1080/2162402X.2018.1553478

Year: 2019

CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy

DOI: 10.1080/21645515.2019.1675459

Year: 2019

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory

DOI: 10.1080/2162402X.2019.1629259

Year: 2019

CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy

DOI: 10.1080/21645515.2018.1504526

Year: 2018

How is Crystallographic Orientation Determined?

Is There a Risk of Exacerbating Existing Inequities?

What are the Applications of Optical Excitation in Nanotechnology?

What are the Future Directions in Electrochromic Nanotechnology?

How are Nanomaterials Improving Environmental Remediation?

How Does Nanotechnology Fit into iGEM?

What is AI-Driven Automation in Nanotechnology?

What are Enantiomers and Why Do They Matter?

What are the Future Trends in Controlling Static Power Consumption?

How Do Nanostructures Affect Light Reflection?

Partnered Content Networks

Relevant Topics